Australian Court Bars Ranbaxy’s Generic Lipitor

Law360, New York (December 19, 2006, 12:00 AM EST) -- In another blow to generic drug maker Ranbaxy Laboratories, the Australian Federal Court has upheld the exclusivity of Pfizer Inc.’s patent covering an active ingredient in anti-cholesterol drug Lipitor in Australia.

Pfizer said Tuesday the federal court in Victoria has affirmed the patent for the ingredient atorvastatin and issued an injunction against the Indian company’s generic version of the drug.

The court allowed Pfizer’s patent to hold on to its exclusivity in Australia until the end of May 2012. Ranbaxy, which filed the suit disputing Pfizer’s...
To view the full article, register now.